Why Viking Therapeutics Stock Is Skyrocketing Today
Shares of Viking Therapeutics (NASDAQ: VKTX) had skyrocketed by 25% as of 11:08 a.m. ET on Tuesday. That big gain came after the company announced results from a phase 1 clinical study evaluating an oral formulation of its experimental obesity drug VK2735.
Viking reported that patients in the study who received oral VK2735 experienced up to 3.3% placebo-adjusted mean weight loss after 28 days. Up to 57% of participants receiving VK2735 achieved weight loss of 5% or more. The safety and tolerability of the experimental drug were also encouraging, with all reported side effects either mild or moderate.
At first glance, you might wonder why there's so much excitement about Viking's phase 1 results. The oral version of VK2735 didn't come close to delivering the 13.1% average weight loss that the injectable version did in its phase 2 study. The key difference is time: That 13.1% weight loss came after 13 weeks of treatment compared to only 28 days for the 3.3% average weight loss achieved by the oral version.
Source Fool.com
Viking Therapeutics Inc Aktie
Viking Therapeutics Inc erfreut sich mäßiger Beliebtheit, mit mehr Buy- als Sell-Einschätzungen.
Für Viking Therapeutics Inc ergibt sich mit einem Kursziel von 110 € eine mögliche Steigerung von über 50% gegenüber 56.72 €.
